Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 793

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 3
Chunk 793
---
ome’s unvested options as part of the transaction, pursuant to the terms of the Omniome merger agreement. Following the achievement of the commercial milestone, $101.3 million of the contingent consideration, which includes certain payroll taxes, was paid during the year ended December 31, 2023. Additionally, 8,988,391 shares were issued at a value of $84.8 million to the former Omniome securityholders.

Fiscal 2024 Form 10-K101

Cash, Cash Equivalents, Restricted Cash, and InvestmentsThe following table summarizes our cash, cash equivalents, restricted cash, and investments:December 31, 2024(in thousands)AmortizedCost Grossunrealizedgains Grossunrealizedlosses FairValue Cash and cash equivalents:Cash and money market funds$55,370 $— $— $55,370 U.S. government & agency securities— — — — Total cash and cash equivalents 55,370 — — 55,370 Investments:Commercial paper — — — — Corporate debt securities 46,746 184 (25)46,905 U.S. government & agency securities287,393 418 (155)287,656 Total investments 334,139 602 (180)334,561 Total cash, cash equivalents, and investments $389,509 $602 $(180)$389,931 Short-term restricted cash$690 $— $— $690 Long-term restricted cash$1,532 $— $— $1,532 December 31, 2023(in thousands)AmortizedCostGrossunrealizedgainsGrossunrealizedlossesFairValueCash and cash equivalents:Cash and money market funds$70,172 $— $— $70,172 Commercial paper — — — — U.S. government & agency securities109,786 13 (60)109,739 Total cash and cash equivalents 179,958 13 (60)179,911 Investments:Commercial paper 9,947 — — 9,947 Corporate debt securities 88,263 373 (57)88,579 U.S. government & agency securities353,029 478 (528)352,979 Total investments 451,239 851 (